ITCI

Intra-Cellular Therapies Inc

A biopharmaceutical company making oral medicines for psychiatric and neurological conditions. Its signature drug, Caplyta, treats schizophrenia, bipolar depression, and major depression in adults. Founded in 2002 by Nobel Prize-winning neuroscientist Paul Greengard, the company is built on his research into how signals travel inside brain cells — the source of its "intra-cellular" name. Johnson & Johnson acquired it in 2025.

No Schedule 13D or 13G filings recorded.